How life sciences leaders move from experimentation to measurable outcomes – without losing trust, compliance, or adoption. Why “AI pilots” aren’t the story anymore Over the last year, the pharma conversation matured. The question isn’t “What did we pilot?” It’s “What’s running in the business and how do we control it?” That shift matters because […]
Some cities have a way of shaping conversations. New Orleans is one of them. The energy is constant. Ideas flow easily. People are open, direct, and unafraid to challenge each other. That same spirit defined the experience at PMSA 2026. The conference floor was busy, but what stood out wasn’t just attendance or enthusiasm. It […]
Every pharma company identifies Key Opinion Leaders. And almost every pharma company does it the same way: a set of business rules based on publication counts, clinical trial participation, and congress presentations, applied manually by medical affairs teams. This approach worked when the scientific landscape was simpler. It does not work when you need to […]
Market access has always been one of the most complex functions in pharma. But in an environment of increasing payer scrutiny, value-based contracting, and patient cost sensitivity, the stakes have never been higher. The companies that win market access are increasingly the ones that bring AI-powered payer intelligence to the table – not after launch, […]
If you lead a commercial function in pharma today, you probably have more dashboards than you know what to do with. Field force performance in one system. Omnichannel engagement in another. Incentive compensation somewhere else. CRM data siloed in Veeva. Marketing mix results locked inside a media agency’s proprietary tool. The irony is unmistakable: the […]
